Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2912-2917

  Yang, Xiaohong Rose ^a   Pfeiffer, Ruth M ^a   Wheeler, William ^b   Yeager, Meredith ^a   Chanock, Stephen ^a   Tucker, Margaret A ^a   Goldstein, Alisa M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

CDKN2A; Cutaneous malignant melanoma; Highrisk family; Modifier gene; Pathway

Indexed keywords

CASPASE 14; CD30 LIGAND; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 9; JANUS KINASE 3; PROTEIN BCL X; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 9; UNCLASSIFIED DRUG; WERNER SYNDROME PROTEIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RISK; CHILD; CONTROLLED STUDY; CUTANEOUS MALIGNANT MELANOMA; DNA REPAIR; FAMILY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MELANOMA; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FAMILY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 72449211941     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24622     Document Type: Article

References (31)

1. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 2001;137:1493-1496 (Pubitemid 33064245)
2. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006;126:660-666
3. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004;23:630.
4. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008;47:175-184
5. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de PB, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
6. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-773 (Pubitemid 32868521)
7. Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de PB, Demenais F. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005;14:2384-2390 (Pubitemid 41437841)
8. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005;14:2208-2212 (Pubitemid 41603269)
9. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van ML, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-779 (Pubitemid 32868522)
10. James MR, Roth RB, Shi MM, Kammerer S, Nelson MR, Stark MS, Dumenil T, Montgomery GW, Hayward NK, Martin NG, Braun A, Duffy DL. BRAF polymorphisms and risk of melanocytic neoplasia. J Invest Dermatol 2005;125:1252-1258
11. Jannot AS, Meziani R, Bertrand G, Gerard B, Descamps V, Archimbaud A, Picard C, Ollivaud L, Basset-Seguin N, Kerob D, Lanternier G, Lebbe C, et al. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet 2005;13:913-920 (Pubitemid 41131738)
12. Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 2001;10:509-513 (Pubitemid 32701638)
13. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-5616 (Pubitemid 30808289)
14. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;40:886-891
15. Muller HK, Malley RC, McGee HM, Scott DK, Wozniak T, Woods GM. Effect of UV radiation on the neonatal skin immune system - implications for melanoma. Photochem Photobiol 2008;84:47-54. (Pubitemid 350265107)
16. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005;104:1962-1967 (Pubitemid 41513181)
17. Gu F, Qureshi AA, Niu T, Kraft P, Guo Q, Hunter DJ, Han J. Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res 2008;18:330-335
18. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31. (Pubitemid 33674866)
19. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007;56: 371-379
20. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21. (Pubitemid 24274055)
21. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006-1010 (Pubitemid 30469967)
22. Reimer RR, Clark WH, Jr, Greene MH, Ainsworth AM, Fraumeni JF, Jr. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978;239:744-746
23. Clark WH, Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978;114:732-738
24. Tucker MA, Greene MH, Clark WH, Jr, Kraemer KH, Fraser MC, Elder DE. Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr 1983;103:65-69
25. Pfeiffer RM, Gail MH, Pee D. Inference for covariates that accounts for ascertainment and random genetic effects in family studies. Biometrika 2001;88:933-948 (Pubitemid 33771543)
26. Dudbridge F, Koeleman BP. Rank truncated product of P-values, with application to genomewide association scans. Genet Epidemiol 2003;25:360-366 (Pubitemid 37486884)
27. Goldstein AM, Martinez M, Tucker MA, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev 2000;9:889-894 (Pubitemid 30743510)
28. Figl A, Scherer D, Nagore E, Bermejo JL, Dickes E, Thirumaran RK, Gast A, Hemminki K, Kumar R, Schadendorf D. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Mutat Res 2009;661:78-84.
29. Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, Doherty V, Kavanagh G, Anderson N, Campbell H, MacKie RM, Melton DW. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis 2007;28:1087-1093 (Pubitemid 47072195)
30. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 1996;5:239-246 (Pubitemid 26116011)
31. Hanneman KK, Cooper KD, Baron ED. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin 2006;24:19-25.